Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427597 | 0.93 | ALDH1A1 (0.47) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6508360 | 0.87 | ALDH1A1 (0.47) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6428309 | 0.85 | GRM7 (0.46) | MAPTALDH1A1MAPK1KDM4ETSHR | |
| SCHEMBL6388619 | 0.82 | LMNA (0.47) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6506320 | 0.82 | L3MBTL1 (0.47) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6500660 | 0.81 | TSHR (0.53) | MAPTALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL6502545 | 0.81 | TSHR (0.53) | MAPTALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL6506436 | 0.81 | TSHR (0.53) | MAPTALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL6505625 | 0.81 | MEN1 (0.43) | ALDH1A1MEN1KMT2AHPGDMAPK1 | |
| SCHEMBL6426299 | 0.80 | GRM7 (0.46) | MAPTALDH1A1KMT2ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | MAPT 3607/4885ALDH1A1 67/4885MEN1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.